About US
Contact us
-
In Supreme Court petition, Merck argues that FDA power shields against liabilityYears after suing drug giant Merck & Co. for serious injuries allegedly caused by osteoporosis drug Fosamax, more than 500 plaintiffs will have to wait to hear the U.S. Solicitor General's take2017/12/6
-
Amgen gets its shot at promoting Repatha to prevent heart attacks and strokesAmgen has its long-awaited approval to tout Repatha as a cardiovascular prevention tool. On the basis ofamassive CV outcomes trial unveiled in March, the FDA blessed the cholesterol drug to fend off h2017/12/5
-
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: reportJohnson & Johnson’s blockbuster anti-TNF drug Remicade fell victim to biosimilar competition in Europe in 2015 and in the U.S. last year, but the impact of the inexpensive copycat drugs has been q2017/12/5
-
Pfizer tops Dow's intellectual heap, with J&J and Merck close behind: studyPfizer is the smartest company in the Dow. That’s according to Talent Growth Advisors' annualassessmentof the 30 companies that make up the Dow Jones Industrial Average. The organization uses an ac2017/12/4
-
Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nodEli Lilly’s Taltz officially has a new arena where it can challenge Novartis’ Cosentyx. On Friday, the FDAgrantedthe immunology drug a green light in psoriatic arthritis, a condition that affects a2017/12/4
-
Amazon in talks with generic drugmakers including Mylan, Sandoz about pharma play: reportThe buzz about Amazon's potential play in the drug business has persisted despite the e-retailing giant's refusal to comment. Now, CNBCreportsthe company has had discussions with generic drugmakers—My2017/12/1
-
Bristol-Myers Squibb takes Opdivo to China's FDA after lung cancer survival winBristol-Myers Squibb is still searching for an Opdivo approval in the all-important first-line lung-cancer space. But in the meantime, it Friday touted strong results in previously treated Chinese pat2017/12/1
-
As lawmakers blast pharma ties, HHS nominee Azar pledges to fight high pricesDrug prices took center stage at a contentious hearing for former Eli Lilly executive Alex Azar, who's up for the top job at the Department of Health and Human Services. During the hearing, many sen2017/11/30
-
J&J, Gates Foundation and NIAID launch efficacy study for their 'global' HIV vaccineRight on the heels of the world's first large-scale HIV vaccine trial in several years, Johnson & Johnson and partners on Thursday pushed their promising "mosaic" vaccine candidate into efficacy2017/11/30
-
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncologyNovartis heart failure med Entresto, which got a slow start after launching to multibillion-dollar sales expectations, would have seen faster uptake, company executives figure—if only it had been an o2017/11/29